International Journal of Hematology

, Volume 107, Issue 6, pp 717–719 | Cite as

Severe graft-versus-host disease after allogeneic hematopoietic stem cell transplantation with residual mogamulizumab concentration

  • Hiroki Hosoi
  • Toshiki Mushino
  • Akinori Nishikawa
  • Hisako Hashimoto
  • Shogo Murata
  • Kazuo Hatanaka
  • Shinobu Tamura
  • Nobuyuki Hanaoka
  • Norio Shimizu
  • Takashi Sonoki
Letter to the Editor
  • 79 Downloads

Notes

Compliance with ethical standards

Conflict of interest

None of the authors have any financial conflicts of interest related with this work.

References

  1. 1.
    Tsubokura Y, Satake A, Hotta M, Yoshimura H, Fujita S, Azuma Y, et al. Successful treatment with mogamulizumab followed by allogeneic hematopoietic stem-cell transplantation in adult T-cell leukemia/lymphoma: a report of two cases. Int J Hematol. 2016;104:744–8.CrossRefPubMedGoogle Scholar
  2. 2.
    Ishitsuka K, Yurimoto S, Kawamura K, Tsuji Y, Iwabuchi M, Takahashi T, et al. Safety and efficacy of mogamulizumab in patients with adult T-cell leukemia-lymphoma in Japan interim results of postmarketing all-case surveillance. Int J Hematol. 2017:106:522–532.CrossRefPubMedGoogle Scholar
  3. 3.
    Fuji S, Inoue Y, Utsunomiya A, Moriuchi Y, Uchimaru K, Choi I, et al. Pretransplantation Anti-CCR4 Antibody Mogamulizumab Against Adult T-Cell Leukemia/Lymphoma Is Associated With Significantly Increased Risks of Severe and Corticosteroid-Refractory Graft-Versus-Host Disease, Nonrelapse Mortality, and Overall Mortality. J Clin Oncol. 2016;34:3426–33.CrossRefPubMedGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2018

Authors and Affiliations

  • Hiroki Hosoi
    • 1
  • Toshiki Mushino
    • 1
  • Akinori Nishikawa
    • 1
  • Hisako Hashimoto
    • 2
  • Shogo Murata
    • 1
  • Kazuo Hatanaka
    • 1
    • 4
  • Shinobu Tamura
    • 1
  • Nobuyuki Hanaoka
    • 1
    • 5
  • Norio Shimizu
    • 3
  • Takashi Sonoki
    • 1
  1. 1.Hematology/OncologyWakayama Medical UniversityWakayamaJapan
  2. 2.Department of Cell TherapyInstitute of Biomedical Research and InnovationKobeJapan
  3. 3.Division of Advanced Biomedical Engineering Research, Center for Stem Cell and Regenerative MedicineInstitute of Research, Tokyo Medical and Dental UniversityTokyoJapan
  4. 4.Department of HematologyOsaka Red Cross HospitalOsakaJapan
  5. 5.Department of General MedicineNational Hospital Organization, Kumamoto Minami HospitalKumamotoJapan

Personalised recommendations